AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of tRNA N6-adenosine threonylcarbamoyltransferase including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into tRNA N6-adenosine threonylcarbamoyltransferase therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of tRNA N6-adenosine threonylcarbamoyltransferase, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on tRNA N6-adenosine threonylcarbamoyltransferase. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of tRNA N6-adenosine threonylcarbamoyltransferase. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for tRNA N6-adenosine threonylcarbamoyltransferase includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
tRNA N6-adenosine threonylcarbamoyltransferase
partner:
Reaxense
upacc:
Q9NPF4
UPID:
OSGEP_HUMAN
Alternative names:
N6-L-threonylcarbamoyladenine synthase; O-sialoglycoprotein endopeptidase; t(6)A37 threonylcarbamoyladenosine biosynthesis protein OSGEP; tRNA threonylcarbamoyladenosine biosynthesis protein OSGEP
Alternative UPACC:
Q9NPF4; Q6IAC3
Background:
The tRNA N6-adenosine threonylcarbamoyltransferase, known by alternative names such as N6-L-threonylcarbamoyladenine synthase and O-sialoglycoprotein endopeptidase, plays a crucial role in the modification of tRNA. This protein is a component of the EKC/KEOPS complex, essential for the formation of a threonylcarbamoyl group on adenosine at position 37 in tRNAs that read codons beginning with adenine. Its activity is vital for the proper translation of genetic information into proteins.
Therapeutic significance:
Given its involvement in Galloway-Mowat syndrome 3, a severe renal-neurological disease, understanding the role of tRNA N6-adenosine threonylcarbamoyltransferase could open doors to potential therapeutic strategies. This protein's function in tRNA modification and its link to developmental and neurological abnormalities highlight its potential as a target for therapeutic intervention.
